Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579700 | 1.00 | OPRD1 (1.00) | OPRD1 | |
| SCHEMBL29406897 | 1.00 | OPRD1 (1.00) | OPRD1 | |
| SCHEMBL8930484 | 1.00 | OPRD1 (1.00) | OPRD1 | |
| SCHEMBL15061454 | 0.94 | OPRD1 (0.88) | OPRD1 | |
| SCHEMBL15061338 | 0.94 | OPRD1 (0.88) | OPRD1 | |
| SCHEMBL15080466 | 0.94 | OPRD1 (0.88) | OPRD1 | |
| SCHEMBL8069224 | 0.93 | OPRD1 (0.86) | OPRD1 | |
| SCHEMBL8930431 | 0.92 | OPRD1 (0.85) | OPRD1 | |
| SCHEMBL8083565 | 0.92 | OPRD1 (0.85) | OPRD1 | |
| SCHEMBL8069255 | 0.91 | OPRD1 (0.83) | OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-09-17 | — | — | US | claimed |
| EP-3432884-A1 | COMBINATION FOR TREATING PAIN | Regents of the University of Minnesota (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165558-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-09-28 | — | — | WO | claimed |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | ENTA HOLDING LLC | 2008-08-14 | — | — | US | claimed |
| EP-0711289-B1 | PIPERAZINE COMPOUNDS USED IN THERAPY | DELTA PHARMACEUTICALS INC (US) | 2000-08-23 | — | — | EP | claimed |
| US-5985880-A | REDUCING, TREATING OR PREVENTING DRUG-MEDIATED RESPIRATORY DEPRESSION IN AN ANIMAL BY ADMINISTERING A .DELTA. RECEPTOR AGONIST COMPOUND | DELTA PHARMACEUTICALS (US) | 1999-11-16 | — | — | US | claimed |
| US-5681830-A | DIARYLMETHYL PIPERAZINE COMPOUNDS HAVING UTILITY IN MEDICAL THERAPY AS RECEPTOR-BINDING SPECIES | DELTA PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | claimed |
| US-5552404-A | COMPOUNDS FOR NEUROTRANSMITTERS FOR ANIMALS | DELTA PHARMACEUTICALS, INC. (US) | 1996-09-03 | — | — | US | claimed |
| EP-0711289-A1 | PIPERAZINE COMPOUNDS USED IN THERAPY | DELTA PHARMACEUTICALS, INC. (US) | 1996-05-15 | — | — | EP | claimed |
| WO-1995004051-A1 | PIPERAZINE COMPOUNDS USED IN THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-09 | — | — | WO | claimed |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2023-12-07 | — | — | US | disclosed |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | DMK PHARMACEUTICALS CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11529340-B2 | Combination for treating pain | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220226312-A1 | OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11246865-B2 | Opioid for use to reduce and/or treat drug addiction | VERSI GROUP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-5681830-A | DIARYLMETHYL PIPERAZINE COMPOUNDS HAVING UTILITY IN MEDICAL THERAPY AS RECEPTOR-BINDING SPECIES | DELTA PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5574159-A | DIARYLMETHYL PIPERAZINES, RECEPTOR BINDING | DELTA PHARMACEUTICALS, INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5552404-A | COMPOUNDS FOR NEUROTRANSMITTERS FOR ANIMALS | DELTA PHARMACEUTICALS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0711289-A1 | PIPERAZINE COMPOUNDS USED IN THERAPY | DELTA PHARMACEUTICALS, INC. (US) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004051-A1 | PIPERAZINE COMPOUNDS USED IN THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885 |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885 |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | OPRL1, ACHE, OPRK1 | OPRD1 6/4885 |
| US-11529340-B2 | Combination for treating pain | OPRL1, ACHE, OPRK1 | OPRD1 6/4885 |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885 |
| US-20220226312-A1 | OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885 |
| US-11246865-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.